O	0	4	Bone
O	5	12	density
O	13	16	and
O	17	26	structure
O	27	29	in
O	30	37	healthy
O	38	52	postmenopausal
O	53	58	women
O	59	66	treated
O	67	71	with
B-intervention	72	82	exemestane
O	83	86	for
O	87	90	the
O	91	98	primary
O	99	109	prevention
O	110	112	of
O	113	119	breast
O	120	126	cancer
O	126	127	:
O	128	129	a
O	130	136	nested
O	137	145	substudy
O	146	148	of
O	149	152	the
O	153	156	MAP
O	156	157	.
O	157	158	3
O	159	169	randomised
O	170	180	controlled
O	181	186	trial
O	186	187	.

O	188	198	Exemestane
O	199	202	can
O	203	210	prevent
O	211	217	breast
O	218	224	cancer
O	225	227	in
O	228	242	postmenopausal
O	243	248	women
O	248	249	.

O	250	257	Because
O	258	260	of
O	261	270	potential
O	271	281	widespread
O	282	285	use
O	285	286	,
O	287	289	we
O	290	298	examined
O	299	302	the
O	303	309	safety
O	310	312	of
O	313	323	exemestane
O	324	326	on
O	327	331	bone
O	332	338	health
O	338	339	.

O	340	342	In
O	343	347	this
O	348	354	nested
O	355	361	safety
O	362	370	substudy
O	371	373	of
O	374	377	the
O	378	381	MAP
O	381	382	.
O	382	383	3
O	384	389	trial
O	390	391	(
O	391	392	a
O	393	403	randomised
O	403	404	,
O	405	412	placebo
O	412	413	-
O	413	423	controlled
O	423	424	,
O	425	431	double
O	431	432	-
O	432	437	blind
O	438	443	trial
O	444	446	of
O	447	457	exemestane
O	458	460	25
O	461	463	mg
O	464	465	a
O	466	469	day
O	470	473	for
O	474	477	the
O	478	485	primary
O	486	496	prevention
O	497	499	of
O	500	506	breast
O	507	513	cancer
O	513	514	)
O	514	515	,
O	516	518	we
O	519	527	included
B-eligibility	528	542	postmenopausal
I-eligibility	543	548	women
I-eligibility	549	553	from
I-eligibility	554	558	five
I-eligibility	559	566	centres
I-eligibility	567	570	who
I-eligibility	571	575	were
I-eligibility	576	584	eligible
I-eligibility	585	587	to
I-eligibility	588	599	participate
I-eligibility	600	602	in
I-eligibility	603	606	MAP
I-eligibility	606	607	.
I-eligibility	607	608	3
I-eligibility	608	609	,
I-eligibility	610	613	not
I-eligibility	614	626	osteoporotic
I-eligibility	626	627	,
I-eligibility	628	631	not
I-eligibility	632	641	receiving
I-eligibility	642	647	drugs
I-eligibility	648	651	for
I-eligibility	652	656	bone
I-eligibility	656	657	-
I-eligibility	657	664	related
I-eligibility	665	674	disorders
I-eligibility	674	675	,
I-eligibility	676	680	with
I-eligibility	681	689	baseline
I-eligibility	690	696	lumbar
I-eligibility	697	702	spine
I-eligibility	702	703	,
I-eligibility	704	709	total
I-eligibility	710	713	hip
I-eligibility	713	714	,
I-eligibility	715	718	and
I-eligibility	719	726	femoral
I-eligibility	727	731	neck
I-eligibility	732	733	T
I-eligibility	733	734	-
I-eligibility	734	740	scores
I-eligibility	741	746	above
I-eligibility	747	748	-
I-eligibility	748	749	2
I-eligibility	749	750	·
I-eligibility	750	751	0
O	751	752	.

O	753	756	The
O	757	764	primary
O	765	773	endpoint
O	774	777	was
B-outcome-Measure	778	785	percent
I-outcome-Measure	786	792	change
I-outcome-Measure	793	797	from
I-outcome-Measure	798	806	baseline
I-outcome-Measure	807	809	to
I-outcome-Measure	810	811	2
I-outcome-Measure	812	817	years
I-outcome-Measure	818	820	in
I-outcome-Measure	821	826	total
I-outcome-Measure	827	837	volumetric
I-outcome-Measure	838	842	bone
I-outcome-Measure	843	850	mineral
I-outcome-Measure	851	858	density
I-outcome-Measure	859	860	(
I-outcome-Measure	860	863	BMD
I-outcome-Measure	863	864	)
I-outcome-Measure	865	867	at
I-outcome-Measure	868	871	the
I-outcome-Measure	872	878	distal
I-outcome-Measure	879	885	radius
O	886	888	by
O	889	893	high
O	893	894	-
O	894	904	resolution
O	905	915	peripheral
O	916	928	quantitative
O	929	931	CT
O	931	932	.

O	933	936	The
O	937	944	primary
O	945	953	analysis
O	954	957	was
O	958	961	per
O	962	970	protocol
O	971	976	using
O	977	978	a
O	979	982	non
O	982	983	-
O	983	994	inferiority
O	995	1001	margin
O	1001	1002	.

O	1003	1007	This
O	1008	1016	analysis
O	1017	1020	was
O	1021	1025	done
O	1026	1033	earlier
O	1034	1038	than
O	1039	1049	originally
O	1050	1057	planned
O	1058	1065	because
O	1066	1068	of
O	1069	1072	the
O	1073	1082	impending
O	1083	1095	announcement
O	1096	1098	of
O	1099	1102	MAP
O	1102	1103	.
O	1103	1104	3
O	1105	1112	results
O	1113	1116	and
O	1117	1127	subsequent
O	1128	1137	unmasking
O	1138	1140	of
O	1141	1149	patients
O	1150	1152	to
O	1153	1162	treatment
O	1163	1173	assignment
O	1173	1174	.

O	1175	1179	This
O	1180	1185	study
O	1186	1188	is
O	1189	1199	registered
O	1200	1204	with
O	1205	1219	ClinicalTrials
O	1219	1220	.
O	1220	1223	gov
O	1223	1224	,
O	1225	1231	number
O	1232	1243	NCT01144468
O	1243	1244	,
O	1245	1248	and
O	1249	1252	has
O	1253	1257	been
O	1258	1266	extended
O	1267	1269	to
O	1270	1271	5
O	1272	1277	years
O	1278	1280	of
O	1281	1289	unmasked
O	1290	1296	follow
O	1296	1297	-
O	1297	1299	up
O	1299	1300	.

B-total-participants	1301	1304	351
O	1305	1310	women
O	1311	1312	(
B-intervention-participants	1312	1315	176
O	1316	1321	given
O	1322	1332	exemestane
O	1332	1333	,
B-control-participants	1334	1337	175
O	1338	1343	given
B-control	1344	1351	placebo
O	1351	1352	;
O	1353	1359	median
O	1360	1363	age
B-age	1364	1366	61
I-age	1366	1367	·
I-age	1367	1368	3
I-age	1369	1374	years
O	1375	1376	[
O	1376	1379	IQR
O	1380	1382	59
O	1382	1383	·
O	1383	1384	2
O	1384	1385	-
O	1385	1387	64
O	1387	1388	·
O	1388	1389	9
O	1389	1390	]
O	1390	1391	)
O	1392	1395	met
O	1396	1399	our
O	1400	1409	inclusion
O	1410	1418	criteria
O	1419	1422	and
O	1423	1432	completed
O	1433	1441	baseline
O	1442	1452	assessment
O	1452	1453	.

O	1454	1456	At
O	1457	1460	the
O	1461	1465	time
O	1466	1468	of
O	1469	1477	clinical
O	1478	1484	cutoff
O	1484	1485	,
B-total-participants	1486	1489	242
O	1490	1495	women
O	1496	1499	had
O	1500	1509	completed
O	1510	1511	2
O	1511	1512	-
O	1512	1516	year
O	1517	1523	follow
O	1523	1524	-
O	1524	1526	up
O	1527	1528	(
B-intervention-participants	1528	1531	124
O	1532	1537	given
O	1538	1548	exemestane
O	1548	1549	,
B-control-participants	1550	1553	118
O	1554	1559	given
O	1560	1567	placebo
O	1567	1568	)
O	1568	1569	.

O	1570	1574	From
O	1575	1583	baseline
O	1584	1586	to
O	1587	1588	2
O	1589	1594	years
O	1594	1595	,
O	1596	1599	the
B-outcome	1600	1604	mean
I-outcome	1605	1612	percent
I-outcome	1613	1619	change
I-outcome	1620	1622	in
I-outcome	1623	1628	total
I-outcome	1629	1639	volumetric
I-outcome	1640	1643	BMD
I-outcome	1644	1646	at
I-outcome	1647	1650	the
I-outcome	1651	1657	distal
I-outcome	1658	1664	radius
O	1665	1668	was
B-iv-cont-mean	1669	1670	-
I-iv-cont-mean	1670	1671	6
I-iv-cont-mean	1671	1672	·
I-iv-cont-mean	1672	1673	1
I-iv-cont-mean	1673	1674	%
O	1675	1676	(
O	1676	1678	95
O	1678	1679	%
O	1680	1682	CI
O	1683	1684	-
O	1684	1685	7
O	1685	1686	·
O	1686	1687	0
O	1688	1690	to
O	1691	1692	-
O	1692	1693	5
O	1693	1694	·
O	1694	1695	2
O	1695	1696	)
O	1697	1699	in
O	1700	1703	the
O	1704	1714	exemestane
O	1715	1720	group
O	1721	1724	and
B-cv-cont-mean	1725	1726	-
I-cv-cont-mean	1726	1727	1
I-cv-cont-mean	1727	1728	·
I-cv-cont-mean	1728	1729	8
I-cv-cont-mean	1729	1730	%
O	1731	1732	(
O	1732	1733	-
O	1733	1734	2
O	1734	1735	·
O	1735	1736	4
O	1737	1739	to
O	1740	1741	-
O	1741	1742	1
O	1742	1743	·
O	1743	1744	2
O	1744	1745	)
O	1746	1748	in
O	1749	1752	the
O	1753	1760	placebo
O	1761	1766	group
O	1767	1768	(
O	1768	1778	difference
O	1779	1780	-
O	1780	1781	4
O	1781	1782	·
O	1782	1783	3
O	1783	1784	%
O	1784	1785	,
O	1786	1788	95
O	1788	1789	%
O	1790	1792	CI
O	1793	1794	-
O	1794	1795	5
O	1795	1796	·
O	1796	1797	3
O	1798	1800	to
O	1801	1802	-
O	1802	1803	3
O	1803	1804	·
O	1804	1805	2
O	1805	1806	;
O	1807	1808	p
O	1808	1809	<
O	1809	1810	0
O	1810	1811	·
O	1811	1815	0001
O	1815	1816	)
O	1816	1817	.

O	1818	1821	The
O	1822	1827	lower
O	1828	1833	limit
O	1834	1836	of
O	1837	1840	the
O	1841	1843	95
O	1843	1844	%
O	1845	1847	CI
O	1848	1851	was
O	1852	1857	lower
O	1858	1862	than
O	1863	1866	our
O	1867	1870	non
O	1870	1871	-
O	1871	1882	inferiority
O	1883	1889	margin
O	1890	1892	of
O	1893	1901	negative
O	1902	1903	4
O	1903	1904	%
O	1905	1906	(
O	1906	1909	one
O	1909	1910	-
O	1910	1915	sided
O	1916	1920	test
O	1921	1924	for
O	1925	1928	non
O	1928	1929	-
O	1929	1940	inferiority
O	1941	1942	p
O	1942	1943	=
O	1943	1944	0
O	1944	1945	·
O	1945	1947	70
O	1947	1948	)
O	1948	1949	,
O	1950	1957	meaning
O	1958	1961	the
O	1962	1972	hypothesis
O	1973	1977	that
O	1978	1988	exemestane
O	1989	1992	was
O	1993	2001	inferior
O	2002	2007	could
O	2008	2011	not
O	2012	2014	be
O	2015	2023	rejected
O	2023	2024	.

O	2025	2027	At
O	2028	2031	the
O	2032	2038	distal
O	2039	2044	tibia
O	2044	2045	,
O	2046	2049	the
B-outcome	2050	2054	mean
I-outcome	2055	2062	percent
I-outcome	2063	2069	change
I-outcome	2070	2072	in
I-outcome	2073	2078	total
I-outcome	2079	2089	volumetric
I-outcome	2090	2093	BMD
I-outcome	2094	2098	from
I-outcome	2099	2107	baseline
I-outcome	2108	2110	to
I-outcome	2111	2112	2
I-outcome	2113	2118	years
O	2119	2122	was
B-iv-cont-mean	2123	2124	-
I-iv-cont-mean	2124	2125	5
I-iv-cont-mean	2125	2126	·
I-iv-cont-mean	2126	2127	0
I-iv-cont-mean	2127	2128	%
O	2129	2130	(
O	2130	2132	95
O	2132	2133	%
O	2134	2136	CI
O	2137	2138	-
O	2138	2139	5
O	2139	2140	·
O	2140	2141	5
O	2142	2144	to
O	2145	2146	-
O	2146	2147	4
O	2147	2148	·
O	2148	2149	4
O	2149	2150	)
O	2151	2153	in
O	2154	2157	the
O	2158	2168	exemestane
O	2169	2174	group
O	2175	2178	and
B-cv-cont-mean	2179	2180	-
I-cv-cont-mean	2180	2181	1
I-cv-cont-mean	2181	2182	·
I-cv-cont-mean	2182	2183	3
I-cv-cont-mean	2183	2184	%
O	2185	2186	(
O	2186	2187	-
O	2187	2188	1
O	2188	2189	·
O	2189	2190	7
O	2191	2193	to
O	2194	2195	-
O	2195	2196	1
O	2196	2197	·
O	2197	2198	0
O	2198	2199	)
O	2200	2202	in
O	2203	2206	the
O	2207	2214	placebo
O	2215	2220	group
O	2221	2222	(
O	2222	2232	difference
O	2233	2234	-
O	2234	2235	3
O	2235	2236	·
O	2236	2237	7
O	2237	2238	%
O	2238	2239	,
O	2240	2242	95
O	2242	2243	%
O	2244	2246	CI
O	2247	2248	-
O	2248	2249	4
O	2249	2250	·
O	2250	2251	3
O	2252	2254	to
O	2255	2256	-
O	2256	2257	3
O	2257	2258	·
O	2258	2259	0
O	2259	2260	;
O	2261	2262	p
O	2262	2263	<
O	2263	2264	0
O	2264	2265	·
O	2265	2269	0001
O	2269	2270	)
O	2270	2271	.

O	2272	2275	The
B-outcome	2276	2280	mean
I-outcome	2281	2288	percent
I-outcome	2289	2295	change
I-outcome	2296	2298	in
I-outcome	2299	2307	cortical
I-outcome	2308	2317	thickness
O	2318	2321	was
B-iv-cont-mean	2322	2323	-
I-iv-cont-mean	2323	2324	7
I-iv-cont-mean	2324	2325	·
I-iv-cont-mean	2325	2326	9
I-iv-cont-mean	2326	2327	%
O	2328	2329	(
O	2329	2331	SD
B-iv-cont-sd	2332	2333	7
I-iv-cont-sd	2333	2334	·
I-iv-cont-sd	2334	2335	3
O	2335	2336	)
O	2337	2339	in
O	2340	2343	the
O	2344	2354	exemestane
O	2355	2360	group
O	2361	2364	and
O	2365	2366	-
O	2366	2367	1
O	2367	2368	·
O	2368	2369	1
O	2369	2370	%
O	2371	2372	(
O	2372	2373	5
O	2373	2374	·
O	2374	2375	7
O	2375	2376	)
O	2377	2379	in
O	2380	2383	the
O	2384	2391	placebo
O	2392	2397	group
B-outcome	2398	2400	at
I-outcome	2401	2404	the
I-outcome	2405	2411	distal
I-outcome	2412	2418	radius
O	2419	2420	(
O	2420	2430	difference
O	2431	2432	-
O	2432	2433	6
O	2433	2434	·
O	2434	2435	8
O	2435	2436	%
O	2436	2437	,
O	2438	2440	95
O	2440	2441	%
O	2442	2444	CI
O	2445	2446	-
O	2446	2447	8
O	2447	2448	·
O	2448	2449	5
O	2450	2452	to
O	2453	2454	-
O	2454	2455	5
O	2455	2456	·
O	2456	2457	0
O	2457	2458	;
O	2459	2460	p
O	2460	2461	<
O	2461	2462	0
O	2462	2463	·
O	2463	2467	0001
O	2467	2468	)
O	2469	2472	and
B-iv-cont-mean	2473	2474	-
I-iv-cont-mean	2474	2475	7
I-iv-cont-mean	2475	2476	·
I-iv-cont-mean	2476	2477	6
I-iv-cont-mean	2477	2478	%
O	2479	2480	(
O	2480	2482	SD
B-cv-cont-sd	2483	2484	5
I-cv-cont-sd	2484	2485	·
I-cv-cont-sd	2485	2486	9
O	2486	2487	)
O	2488	2490	in
O	2491	2494	the
O	2495	2505	exemestane
O	2506	2511	group
O	2512	2515	and
B-cv-cont-mean	2516	2517	-
I-cv-cont-mean	2517	2518	0
I-cv-cont-mean	2518	2519	·
I-cv-cont-mean	2519	2520	7
I-cv-cont-mean	2520	2521	%
O	2522	2523	(
O	2523	2524	4
O	2524	2525	·
O	2525	2526	9
O	2526	2527	)
O	2528	2530	in
O	2531	2534	the
O	2535	2542	placebo
O	2543	2548	group
B-outcome	2549	2551	at
I-outcome	2552	2555	the
I-outcome	2556	2562	distal
I-outcome	2563	2568	tibia
O	2569	2570	(
O	2570	2580	difference
O	2581	2582	-
O	2582	2583	6
O	2583	2584	·
O	2584	2585	9
O	2585	2586	%
O	2586	2587	,
O	2588	2589	-
O	2589	2590	8
O	2590	2591	·
O	2591	2592	4
O	2593	2595	to
O	2596	2597	-
O	2597	2598	5
O	2598	2599	·
O	2599	2600	5
O	2600	2601	;
O	2602	2603	p
O	2603	2604	<
O	2604	2605	0
O	2605	2606	·
O	2606	2610	0001
O	2610	2611	)
O	2611	2612	.

O	2613	2620	Decline
O	2621	2623	in
B-outcome	2624	2629	areal
I-outcome	2630	2633	BMD
O	2633	2634	,
O	2635	2637	as
O	2638	2646	measured
O	2647	2649	by
O	2650	2654	dual
O	2654	2655	-
O	2655	2661	energy
O	2662	2663	x
O	2663	2664	-
O	2664	2667	ray
O	2668	2682	absorptiometry
O	2682	2683	,
O	2684	2686	in
O	2687	2690	the
O	2691	2701	exemestane
O	2702	2707	group
O	2708	2716	compared
O	2717	2721	with
O	2722	2725	the
O	2726	2733	placebo
O	2734	2739	group
O	2740	2748	occurred
B-outcome	2749	2751	at
I-outcome	2752	2755	the
I-outcome	2756	2762	lumbar
I-outcome	2763	2768	spine
O	2769	2770	(
B-iv-cont-mean	2770	2771	-
I-iv-cont-mean	2771	2772	2
I-iv-cont-mean	2772	2773	·
I-iv-cont-mean	2773	2774	4
I-iv-cont-mean	2774	2775	%
O	2776	2777	[
O	2777	2779	95
O	2779	2780	%
O	2781	2783	CI
O	2784	2785	-
O	2785	2786	3
O	2786	2787	·
O	2787	2788	1
O	2789	2791	to
O	2792	2793	-
O	2793	2794	1
O	2794	2795	·
O	2795	2796	7
O	2796	2797	]
O	2798	2808	exemestane
O	2809	2811	vs
B-cv-cont-mean	2812	2813	-
I-cv-cont-mean	2813	2814	0
I-cv-cont-mean	2814	2815	·
I-cv-cont-mean	2815	2816	5
I-cv-cont-mean	2816	2817	%
O	2818	2819	[
O	2819	2820	-
O	2820	2821	1
O	2821	2822	·
O	2822	2823	1
O	2824	2826	to
O	2827	2828	0
O	2828	2829	·
O	2829	2830	2
O	2830	2831	]
O	2832	2839	placebo
O	2839	2840	;
O	2841	2851	difference
O	2852	2853	-
O	2853	2854	1
O	2854	2855	·
O	2855	2856	9
O	2856	2857	%
O	2857	2858	,
O	2859	2861	95
O	2861	2862	%
O	2863	2865	CI
O	2866	2867	-
O	2867	2868	2
O	2868	2869	·
O	2869	2870	9
O	2871	2873	to
O	2874	2875	-
O	2875	2876	1
O	2876	2877	·
O	2877	2878	0
O	2878	2879	;
O	2880	2881	p
O	2881	2882	<
O	2882	2883	0
O	2883	2884	·
O	2884	2888	0001
O	2888	2889	)
O	2889	2890	,
B-outcome	2891	2896	total
I-outcome	2897	2900	hip
O	2901	2902	(
B-iv-cont-mean	2902	2903	-
I-iv-cont-mean	2903	2904	1
I-iv-cont-mean	2904	2905	·
I-iv-cont-mean	2905	2906	8
I-iv-cont-mean	2906	2907	%
O	2908	2909	[
O	2909	2910	-
O	2910	2911	2
O	2911	2912	·
O	2912	2913	3
O	2914	2916	to
O	2917	2918	-
O	2918	2919	1
O	2919	2920	·
O	2920	2921	2
O	2921	2922	]
O	2923	2933	exemestane
O	2934	2936	vs
B-cv-cont-mean	2937	2938	-
I-cv-cont-mean	2938	2939	0
I-cv-cont-mean	2939	2940	·
I-cv-cont-mean	2940	2941	6
I-cv-cont-mean	2941	2942	%
O	2943	2944	[
O	2944	2945	-
O	2945	2946	1
O	2946	2947	·
O	2947	2948	1
O	2949	2951	to
O	2952	2953	-
O	2953	2954	0
O	2954	2955	·
O	2955	2956	1
O	2956	2957	]
O	2958	2965	placebo
O	2965	2966	;
O	2967	2977	difference
O	2978	2979	-
O	2979	2980	1
O	2980	2981	·
O	2981	2982	2
O	2982	2983	%
O	2983	2984	,
O	2985	2986	-
O	2986	2987	1
O	2987	2988	·
O	2988	2989	9
O	2990	2992	to
O	2993	2994	-
O	2994	2995	0
O	2995	2996	·
O	2996	2997	4
O	2997	2998	;
O	2999	3000	p
O	3000	3001	=
O	3001	3002	0
O	3002	3003	·
O	3003	3006	004
O	3006	3007	)
O	3007	3008	,
O	3009	3012	and
B-outcome	3013	3020	femoral
I-outcome	3021	3025	neck
O	3026	3027	(
B-iv-cont-mean	3027	3028	-
I-iv-cont-mean	3028	3029	2
I-iv-cont-mean	3029	3030	·
I-iv-cont-mean	3030	3031	4
I-iv-cont-mean	3031	3032	%
O	3033	3034	[
O	3034	3035	-
O	3035	3036	3
O	3036	3037	·
O	3037	3038	2
O	3039	3041	to
O	3042	3043	-
O	3043	3044	1
O	3044	3045	·
O	3045	3046	7
O	3046	3047	]
O	3048	3058	exemestane
O	3059	3061	vs
B-cv-cont-mean	3062	3063	-
I-cv-cont-mean	3063	3064	0
I-cv-cont-mean	3064	3065	·
I-cv-cont-mean	3065	3066	8
I-cv-cont-mean	3066	3067	%
O	3068	3069	[
O	3069	3070	-
O	3070	3071	1
O	3071	3072	·
O	3072	3073	5
O	3074	3076	to
O	3077	3078	0
O	3078	3079	·
O	3079	3080	1
O	3080	3081	]
O	3082	3089	placebo
O	3089	3090	;
O	3091	3101	difference
O	3102	3103	-
O	3103	3104	1
O	3104	3105	·
O	3105	3106	6
O	3106	3107	%
O	3107	3108	,
O	3109	3110	-
O	3110	3111	2
O	3111	3112	·
O	3112	3113	7
O	3114	3116	to
O	3117	3118	-
O	3118	3119	0
O	3119	3120	·
O	3120	3121	6
O	3121	3122	;
O	3123	3124	p
O	3124	3125	=
O	3125	3126	0
O	3126	3127	·
O	3127	3130	002
O	3130	3131	)
O	3131	3132	.

O	3133	3134	2
O	3135	3140	years
O	3141	3143	of
O	3144	3153	treatment
O	3154	3158	with
O	3159	3169	exemestane
O	3170	3177	worsens
O	3178	3181	age
O	3181	3182	-
O	3182	3189	related
B-outcome	3190	3194	bone
I-outcome	3195	3199	loss
O	3200	3202	in
O	3203	3217	postmenopausal
O	3218	3223	women
O	3224	3231	despite
O	3232	3239	calcium
O	3240	3243	and
O	3244	3251	vitamin
O	3252	3253	D
O	3254	3269	supplementation
O	3269	3270	.

O	3271	3276	Women
O	3277	3288	considering
O	3289	3299	exemestane
O	3300	3303	for
O	3304	3307	the
O	3308	3315	primary
O	3316	3326	prevention
O	3327	3329	of
O	3330	3336	breast
O	3337	3343	cancer
O	3344	3350	should
O	3351	3356	weigh
O	3357	3362	their
O	3363	3373	individual
O	3374	3379	risks
O	3380	3383	and
O	3384	3392	benefits
O	3392	3393	.

O	3394	3397	For
O	3398	3403	women
O	3404	3410	taking
O	3411	3421	exemestane
O	3421	3422	,
O	3423	3430	regular
O	3431	3435	bone
O	3436	3446	monitoring
O	3447	3451	plus
O	3452	3460	adequate
O	3461	3468	calcium
O	3469	3472	and
O	3473	3480	vitamin
O	3481	3482	D
O	3483	3498	supplementation
O	3499	3502	are
O	3503	3512	important
O	3512	3513	.

O	3514	3516	To
O	3517	3523	assess
O	3524	3527	the
O	3528	3534	effect
O	3535	3537	of
O	3538	3541	our
O	3542	3550	findings
O	3551	3553	on
O	3554	3562	fracture
O	3563	3567	risk
O	3567	3568	,
O	3569	3573	long
O	3573	3574	-
O	3574	3578	term
O	3579	3585	follow
O	3585	3586	-
O	3586	3588	up
O	3589	3591	is
O	3592	3598	needed
O	3598	3599	.

O	3600	3608	Canadian
O	3609	3615	Breast
O	3616	3622	Cancer
O	3623	3631	Research
O	3632	3640	Alliance
O	3641	3642	(
O	3642	3650	Canadian
O	3651	3661	Institutes
O	3662	3664	of
O	3665	3671	Health
O	3672	3680	Research
O	3680	3681	/
O	3681	3689	Canadian
O	3690	3696	Cancer
O	3697	3704	Society
O	3704	3705	)
O	3705	3706	.
